ESOU 2019
ESOU 2019 Prostate Cancer
- ESOU 2019: Treatment of Gleason 3+4 in a Multidisciplinary Scenario: Surgery
- ESOU 2019: Treatment of Gleason 3+4 in a Multidisciplinary Scenario: Hypofractionation Radiation Therapy
- ESOU 2019: Treatment of Gleason 3+4 in a Multidisciplinary Scenario: Focal Therapy
- ESOU 2019: Treatment of Gleason 3+4 in a Multidisciplinary Scenario: Active Surveillance
- ESOU 2019: An Update in Prostate Cancer Prevention
ESOU 2019 Kidney Cancer
- ESOU 2019: Debate: T2 Renal Tumors Best Surgical Treatment: Radical Nephrectomy
- ESOU 2019: Debate: T2 Renal Tumors Best Surgical Treatment: Partial Nephrectomy
- ESOU 2019: Revolution in the First Line Treatment for Metastatic Renal Cell Carcinoma: Where Do We Stand?
- ESOU 2019: Adjuvant Therapy after Nephrectomy for High Risk Renal Cell Carcinoma: The Oncologist's Perspective
- ESOU 2019: Cytoreductive Nephrectomy: What are the Current Recommendations?
ESOU 2019 Bladder Cancer
- ESOU 2019: Best of Uro-Oncology 2018 – Urothelial Cancer
- ESOU 2019: Treatment of Positive Pelvic Lymph Nodes: Systemic Treatments
- ESOU 2019: New Perspectives in Upper Tract Urothelial Cancer Treatment
- ESOU 2019: Conservative Management of Upper Tract Urinary Cancer
- ESOU 2019: Optimizing Functional Outcomes in Radical Cystectomy: Prostate Sparing Approaches
ESOU 2019 Penile and Testis Cancer
- ESOU 2019: Minimally Invasive Inguinal Lymphadenectomy
- ESOU 2019: Molecular Markers for Staging and Monitoring Testis Cancer
- ESOU 2019: Best of Uro-Oncology 2018: Penile and Testis Cancer
- ESOU 2019: The Role of RPLND in Tumor Marker Negative Stage IIA-B: PRO
- ESOU 2019: The Role of RPLND in Tumor Marker Negative Stage IIA-B: CON